| __timestamp | Genmab A/S | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 4042025 |
| Thursday, January 1, 2015 | 91224000 | 5279557 |
| Friday, January 1, 2016 | 102413000 | 8073913 |
| Sunday, January 1, 2017 | 146987000 | 44864073 |
| Monday, January 1, 2018 | 213695000 | 53488904 |
| Tuesday, January 1, 2019 | 342000000 | 65896361 |
| Wednesday, January 1, 2020 | 661000000 | 69968267 |
| Friday, January 1, 2021 | 1283000000 | 92047281 |
| Saturday, January 1, 2022 | 2676000000 | 131819000 |
| Sunday, January 1, 2023 | 3297000000 | 87501000 |
| Monday, January 1, 2024 | 3790000000 |
Unleashing insights
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Genmab A/S and Pharming Group N.V. have showcased contrasting trajectories in their SG&A expenditures.
Genmab A/S has seen a staggering increase in SG&A expenses, growing from approximately $80 million in 2014 to over $3.3 billion by 2023. This represents a growth of over 4,000%, highlighting Genmab's aggressive expansion and investment in administrative capabilities. In contrast, Pharming Group N.V. has maintained a more conservative approach, with SG&A expenses rising from around $4 million in 2014 to about $88 million in 2023, a growth of roughly 2,100%.
This divergence in spending patterns reflects differing strategic priorities and market positions, offering valuable insights into the operational strategies of these two biotech firms.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Pharming Group N.V.
Comparing SG&A Expenses: Novartis AG vs Pharming Group N.V. Trends and Insights
Vertex Pharmaceuticals Incorporated vs Genmab A/S: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Genmab A/S and Blueprint Medicines Corporation
Genmab A/S vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Pharming Group N.V.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Pharming Group N.V.
Comparing SG&A Expenses: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.